Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN®) and ChAdOx1 nCoV-19 (COVISHIELD™) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational study.

Lancet Reg Health Southeast Asia · 2024 · PMC10934322 · PMID 38482152

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

When analysed for individual cytokines, CovishieldTM elicited significant IFNγ, IL2 and TNF responses in CD4 T cells, whereas Covaxin® elicited IL2 and TNF responses, however these did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.